Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: Rapid engraftment in bone marrow

被引:28
作者
Misawa, M
Kai, S
Okada, M
Nakajima, T
Nomura, K
Wakae, T
Toda, A
Itoi, H
Takatsuka, H
Itsukuma, T
Nishioka, K
Fujimori, Y
Ogawa, H
Hara, H
机构
[1] Hyogo Med Univ, Lab Cell Transplantat, Inst Adv Med Sci, Nishinomiya, Hyogo 6638501, Japan
[2] Hyogo Med Univ, Div Hematol, Dept Internal Med, Nishinomiya, Hyogo 6638501, Japan
[3] Hyogo Med Univ, Div Blood Transfus, Nishinomiya, Hyogo 6638501, Japan
[4] Uegahara Hosp, Nishinomiya, Hyogo, Japan
关键词
hematologic malignancy; cord blood transplantation; adult; reduced-intensity conditioning;
D O I
10.1532/IJH97.05124
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Reduced-intensity (RI) conditioning followed by cord blood transplantation (CBT) is a new treatment modality, but failure to engraft is a major concern. We describe 12 patients with advanced hematologic malignancies who underwent RI conditioning and CBT with a conditioning regimen consisting of 200 mg/m(2) fludarabine (Flu), 50 mg/kg cyclophosphamide (CY), and 3 Gy total body irradiation (TBI). Cyclosporin A and/or methotrexate were used for graft-versus-host disease prophylaxis. Cord blood grafts were not mismatched for more than 2 serologically defined HLA alleles but were later found by high-resolution DNA typing to be mismatched for 2 to 4 alleles in most cases. Short tandem repeat analysis of bone marrow cells at day 14 showed complete donor chimerism in 6 of the patients and mixed chimerism in 5, indicating rapid engraftment in the bone marrow, whereas the remaining patient experienced graft rejection. Neutrophil recovery was achieved at a median of day 17 (range, days 11-24) in 10 of the 11 patients with marrow chimerism at day 14. Of these 10 patients, however, transplantation-related mortality within 100 days occurred in 4 patients who showed failed platelet recovery and a lack of durable engraftment. Overall survival and disease-free survival rates were 41.7% and 33.3%, respectively. These results show that CB mismatched at 2 to 4 HLA alleles and transplanted with the Flu/CY/3 Gy TBI regimen is able to engraft in the bone marrow as early as day 14.
引用
收藏
页码:74 / 79
页数:6
相关论文
共 25 条
[1]  
BANNER NR, 2001, MED INTELL UNIT, V21, P1
[2]   Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning [J].
Barker, JN ;
Weisdorf, DJ ;
DeFor, TE ;
Blazar, BR ;
Miller, JS ;
Wagner, JE .
BLOOD, 2003, 102 (05) :1915-1919
[3]   REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
APPELBAUM, FR ;
BUCKNER, CD ;
PETERSEN, FB ;
FISHER, LD ;
CLIFT, RA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1562-1568
[4]   LOCUS-SPECIFIC AMPLIFICATION OF HLA CLASS-I GENES FROM GENOMIC DNA - LOCUS-SPECIFIC SEQUENCES IN THE FIRST AND 3RD INTRONS OF HLA-A, HLA-B, AND HLA-C ALLELES [J].
CEREB, N ;
MAYE, P ;
LEE, S ;
KONG, Y ;
YANG, SY .
TISSUE ANTIGENS, 1995, 45 (01) :1-11
[5]   Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens [J].
Chao, NJ ;
Koh, LP ;
Long, GD ;
Gasparetto, C ;
Horwitz, M ;
Morris, A ;
Lassiter, M ;
Sullivan, KM ;
Rizzieri, DA .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (08) :569-575
[6]   Results of an unrelated transplant search strategy using partially HLA-mismatched cord blood as an immediate alternative to HLA-matched bone marrow [J].
Dalle, JH ;
Duval, M ;
Moghrabi, A ;
Wagner, E ;
Vachon, MF ;
Barrette, S ;
Bernstein, M ;
Champagne, J ;
David, M ;
Demers, J ;
Rousseau, P ;
Winikoff, R ;
Champagne, MA .
BONE MARROW TRANSPLANTATION, 2004, 33 (06) :605-611
[7]   Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation [J].
Elmaagacli, AH ;
Beelen, DW ;
Trenn, G ;
Schmidt, O ;
Nahler, M ;
Schaefer, UW .
BONE MARROW TRANSPLANTATION, 1999, 23 (08) :771-777
[8]   Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice [J].
Gluckman, E ;
Rocha, V ;
Arcese, W ;
Michel, G ;
Sanz, G ;
Chan, KW ;
Takahashi, TA ;
Ortega, J ;
Filipovich, A ;
Locatelli, F ;
Asano, S ;
Fagioli, F ;
Vowels, M ;
Sirvent, A ;
Laporte, JP ;
Tiedemann, K ;
Amadori, S ;
Abecassis, M ;
Bordigoni, P ;
Diez, B ;
Shaw, PJ ;
Vora, A ;
Caniglia, M ;
Garnier, F ;
Ionescu, I ;
Garcia, J ;
Koegler, G ;
Rebulla, P ;
Chevret, S .
EXPERIMENTAL HEMATOLOGY, 2004, 32 (04) :397-407
[9]   Outcome of cord-blood transplantation from related and unrelated donors [J].
Gluckman, E ;
Rocha, V ;
BoyerChammard, A ;
Locatelli, F ;
Arcese, W ;
Pasquini, R ;
Ortega, J ;
Souillet, G ;
Ferreira, E ;
Laporte, JP ;
Fernandez, M ;
Chastang, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :373-381
[10]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304